GSK commits $30 billion to advanced manufacturing in US amid Trump pressure

In late 2024, the British pharmaceutical company GlaxoSmithKline (GSK) announced a significant investment in the United States, amounting to $30 billion aimed at enhancing advanced manufacturing capabilities. This move comes as a response to pressure from then-President Donald Trump, who urged foreign companies to invest in the American economy, particularly in the wake of the COVID-19 pandemic's impact on global supply chains. GSK's decision is likely to generate thousands of jobs in the US, strengthening local economies and elevating the country's position in global pharmaceutical manufacturing. Moreover, the investment is intended to facilitate faster vaccine development and production processes, a strategic shift propelled by lessons learned during the pandemic. This proactive approach by GSK also reflects the broader industry trend of enhancing domestic production capabilities to meet both local and global healthcare demands, ensuring timely access to critical medications and vaccines. As manufacturers adapt to the new realities of market demands and geopolitical influences, such substantial investments signal confidence in the US economy as an attractive destination for future growth, potentially influencing other pharmaceutical companies to follow suit.